TERNS PHARMACEUTICALS INC (TERN) Stock News

NASDAQ:TERN - US8808811074 - Common Stock

7.06 USD

-0.38 (-5.11%)

Last: 9/4/2025, 8:00:01 PM

7.05 USD

-0.01 (-0.14%)

After Hours: 9/4/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TERN Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

14 days ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

a month ago - By: Benzinga - Mentions: LLY NVO VKTX GPCR

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

a month ago - By: The Motley Fool

Terns (TERN) Q2 Net Loss Narrows 16%

a month ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

a month ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

a month ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

a month ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

6 months ago - By: The Motley Fool

This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street

2 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

2 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

3 months ago - By: Benzinga - Mentions: RGC SMLR GLMD IRD ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

3 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

3 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

4 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

4 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

4 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

4 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

4 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

4 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

4 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

5 months ago - By: Bloomberg - Mentions: PFE VKTX GPCR MTSR

Pfizer Setback Spurs Rise in Obesity Developers on M&A Hopes

5 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

5 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

6 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

6 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

6 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

6 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

6 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

6 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

6 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

6 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

7 months ago - By: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors